Venetoclax with decitabine or azacitidine for AML

Venetoclax, an oral selective inhibitor of the antiapoptotic protein BCL-2, shows encouraging anticancer activity and tolerable safety in older patients with acute myeloid leukaemia (AML) who are unfit for traditional chemotherapy, according to new research.